1. Scrip

Alnylam Enjoys Autumn in Paris With hATTR Win Over Ionis

 
• By Kevin Grogan

Patisiran data impresses more than inotersen but Ionis is the first to file with a European submission.

Paris
Both Alnylam and Ionis seek to be top of the tree in hATTR • Source: Shutterstock

Alnylam Pharmaceuticals Inc.'s patisiran seems to be on course to become the standard of care for hereditary ATTR (hATTR) amyloidosis after the full data set from the APOLLO study on the first RNAi therapeutic to succeed in a late-stage trial were unveiled to acclaim at a conference in Paris.

In September, the top-line results from the APOLLO study led to a 52% leap in Alnylam's share price and the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Rare Diseases

More from Scrip

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

Gilead’s Yeztugo Gets US Approval For Twice-Yearly PrEP

 
• By Alexandra Shimmings

The first twice-yearly option for HIV prevention has been approved by the US Food and Drug Administration in an advance that “brings us closer than ever to ending the HIV epidemic,” said CEO Daniel O’Day.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.